| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 1.96B | 14.87 | 378.37 | 33.97% | 29.28% | 21.28% | 2.25% | 0.21 |
| ARGXargenx SE | 50.33B | 813.24 | 63.63 | 78.6% | 23.34% | 15.14% | 0.01 | |
| INVAInnoviva, Inc. | 1.48B | 19.76 | 54.89 | 15.54% | 32.78% | 12.61% | 12.75% | 0.65 |
| GLPGGalapagos N.V. | 2.24B | 34.03 | 30.38 | 14.99% | -151.94% | -15.16% | 0.00 | |
| PTGXProtagonist Therapeutics, Inc. | 5.3B | 84.75 | 20.04 | 6.24% | 21.94% | 7.11% | 3.45% | 0.02 |
| ALMSAlumis Inc. Common Stock | 2.84B | 24.17 | -2.33 | -11.08% | -63.71% | 0.12 | ||
| PHATPhathom Pharmaceuticals, Inc. | 1.17B | 14.98 | -2.83 | 80.01% | -186.53% | |||
| ORKAOruka Therapeutics, Inc. | 1.57B | 32.50 | -6.51 | -22.44% | 0.00 |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Sales/Revenue | 0 | 0 |
| Revenue Growth % | - | - |
| Cost of Goods Sold | 0 | 0 |
| COGS % of Revenue | - | - |
| Gross Profit | 0 | 0 |
| Gross Margin % | - | - |
| Gross Profit Growth % | - | - |
| Operating Expenses | 19.3K | 365.06K |
| OpEx % of Revenue | - | - |
| Selling, General & Admin | 19.3K | 290.39K |
| SG&A % of Revenue | - | - |
| Research & Development | 0 | 0 |
| R&D % of Revenue | - | - |
| Other Operating Expenses | 0 | 74.68K |
| Operating Income | -19.3K | -365.06K |
| Operating Margin % | - | - |
| Operating Income Growth % | - | -17.92% |
| EBITDA | -17.48K | -290.39K |
| EBITDA Margin % | - | - |
| EBITDA Growth % | - | -15.61% |
| D&A (Non-Cash Add-back) | 1.81K | 0 |
| EBIT | -19.3K | -290.39K |
| Net Interest Income | 0 | 0 |
| Interest Income | 0 | 0 |
| Interest Expense | 0 | 0 |
| Other Income/Expense | 100 | 3.56K |
| Pretax Income | -19.2K | -361.51K |
| Pretax Margin % | - | - |
| Income Tax | 0 | 0 |
| Effective Tax Rate % | 1% | 1% |
| Net Income | -19.2K | -361.51K |
| Net Margin % | - | - |
| Net Income Growth % | - | -17.83% |
| Net Income (Continuing) | -19.2K | -361.51K |
| Discontinued Operations | 0 | 0 |
| Minority Interest | 0 | 0 |
| EPS (Diluted) | -0.00 | -0.01 |
| EPS Growth % | - | - |
| EPS (Basic) | -0.00 | -0.01 |
| Diluted Shares Outstanding | 42M | 27.75M |
| Basic Shares Outstanding | 42M | 27.75M |
| Dividend Payout Ratio | - | - |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Total Current Assets | 74.37K | 517.93K |
| Cash & Short-Term Investments | 74.37K | 148.89K |
| Cash Only | 74.37K | 148.89K |
| Short-Term Investments | 0 | 0 |
| Accounts Receivable | 0 | 0 |
| Days Sales Outstanding | - | - |
| Inventory | 0 | 0 |
| Days Inventory Outstanding | - | - |
| Other Current Assets | 0 | 367.87K |
| Total Non-Current Assets | 0 | 0 |
| Property, Plant & Equipment | 0 | 0 |
| Fixed Asset Turnover | - | - |
| Goodwill | 0 | 0 |
| Intangible Assets | 0 | 0 |
| Long-Term Investments | 0 | 0 |
| Other Non-Current Assets | 0 | 0 |
| Total Assets | 74.37K | 517.93K |
| Asset Turnover | - | - |
| Asset Growth % | - | 5.96% |
| Total Current Liabilities | 14.28K | 14.57K |
| Accounts Payable | 0 | 5K |
| Days Payables Outstanding | - | - |
| Short-Term Debt | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 |
| Other Current Liabilities | -600 | 0 |
| Current Ratio | 5.21x | 35.54x |
| Quick Ratio | 5.21x | 35.54x |
| Cash Conversion Cycle | - | - |
| Total Non-Current Liabilities | 0 | 0 |
| Long-Term Debt | 0 | 0 |
| Capital Lease Obligations | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 |
| Total Liabilities | 14.28K | 14.57K |
| Total Debt | 0 | 0 |
| Net Debt | -74.37K | -148.89K |
| Debt / Equity | - | - |
| Debt / EBITDA | - | - |
| Net Debt / EBITDA | - | - |
| Interest Coverage | - | - |
| Total Equity | 60.09K | 503.36K |
| Equity Growth % | - | 7.38% |
| Book Value per Share | 0.00 | 0.02 |
| Total Shareholders' Equity | 60.09K | 503.36K |
| Common Stock | 60 | 2.4K |
| Retained Earnings | -260.94K | -622.45K |
| Treasury Stock | 0 | 0 |
| Accumulated OCI | 0 | 0 |
| Minority Interest | 0 | 0 |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Cash from Operations | -120 | -555.58K |
| Operating CF Margin % | - | - |
| Operating CF Growth % | - | -4628.79% |
| Net Income | -19.2K | -361.51K |
| Depreciation & Amortization | 1.81K | 0 |
| Stock-Based Compensation | 0 | 0 |
| Deferred Taxes | 0 | 0 |
| Other Non-Cash Items | 0 | 74.68K |
| Working Capital Changes | 17.26K | -268.75K |
| Change in Receivables | 0 | 0 |
| Change in Inventory | 2.99K | 0 |
| Change in Payables | 0 | 5K |
| Cash from Investing | 0 | 0 |
| Capital Expenditures | 0 | 0 |
| CapEx % of Revenue | - | - |
| Acquisitions | - | - |
| Investments | - | - |
| Other Investing | 0 | 0 |
| Cash from Financing | 72.06K | 630.1K |
| Debt Issued (Net) | - | - |
| Equity Issued (Net) | - | - |
| Dividends Paid | 0 | 0 |
| Share Repurchases | - | - |
| Other Financing | 3K | 0 |
| Net Change in Cash | - | - |
| Free Cash Flow | -120 | -555.58K |
| FCF Margin % | - | - |
| FCF Growth % | - | -4628.79% |
| FCF per Share | -0.00 | -0.02 |
| FCF Conversion (FCF/Net Income) | 0.01x | 1.54x |
| Interest Paid | 0 | 0 |
| Taxes Paid | 0 | 0 |
| Metric | 2023 | 2024 |
|---|---|---|
| Return on Equity (ROE) | -31.95% | -128.32% |
| Return on Invested Capital (ROIC) | - | -160.97% |
| FCF Conversion | 0.01x | 1.54x |
Curanex Pharmaceuticals Inc Common Stock (CURX) grew revenue by 0.0% over the past year. Growth has been modest.
Curanex Pharmaceuticals Inc Common Stock (CURX) reported a net loss of $1.2M for fiscal year 2024.
Curanex Pharmaceuticals Inc Common Stock (CURX) has a return on equity (ROE) of -128.3%. Negative ROE indicates the company is unprofitable.
Curanex Pharmaceuticals Inc Common Stock (CURX) had negative free cash flow of $9.9M in fiscal year 2024, likely due to heavy capital investments.